REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Lek S.A. (Poland)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Lek S.A. Profile Updated: October 12, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Polish Download a sample report

Lek S.A. is a company located in Strykow, Poland. It is part of the Sandoz group, a global leader in the production of generic drugs. The company operates under the name Sandoz in Poland since January 2010, continuing the tradition of the Lek Polska and Hexal brands. Sandoz in Poland is one of the leaders in the market for generic drugs.

Headquarters
Ul. Podlipie 16
Strykow; Lodzkie; Postal Code: 95-010

Contact Details: Purchase the Lek S.A. report to view the information.

Website: http://lek-sa.pl

Basic Information
Total Employees:
Purchase the Lek S.A. report to view the information.
Outstanding Shares:
Purchase the Lek S.A. report to view the information.
Registered Capital:
Purchase the Lek S.A. report to view the information.
Financial Auditors:
Purchase the Lek S.A. report to view the information.
Incorporation Date:
November 16, 2001
Key Executives
Purchase this report to view the information.
President
Purchase this report to view the information.
Management Board Member
Purchase this report to view the information.
Management Board Member
Purchase this report to view the information.
Management Board Member
Purchase this report to view the information.
Management Board Member
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Lek S.A. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Net sales revenue
37.65%▲
Total operating revenue
37.86%▲
Operating profit (EBIT)
-5.32%▼
EBITDA
-2.45%▼
Net Profit (Loss) for the Period
-11.3%▼
Total assets
28.32%▲
Total equity
10.34%▲
Operating Profit Margin (ROS)
-1.67%▼
Net Profit Margin
-1.38%▼
Return on Equity (ROE)
-2.29%▼
Quick Ratio
-0.07%▼
Cash Ratio
-0%

Similar companies

Zaklady Farmaceutyczne "Polpharma" S.A.
 
Bayer Sp. z o.o.
"Roche Polska" Sp. z o.o.
 
Teva Operations Poland Sp. z o.o.
Adamed Pharma S.A.
 
Centrala Farmaceutyczna "Cefarm" S.A.
Aflofarm Farmacja Polska Sp. z o.o.
 
Delpharm Poznan S.A.
"Usp Zdrowie" Sp. z o.o.
 
Sanofi Sp. z o.o.

Related EMIS Industry Reports

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo